May 13, 2024
An mRNA therapeutic’s path to market-readiness is filled with challenges, particularly when it comes to efficiency and yield. Fitting a new therapy like mRNA into a process tailored for well-established monoclonal antibodies, could hamper reaching its full potential (think efficiency, processing time and impact on yields). At Cytiva, we’re working to change this.
We’re introducing a new addition to our T-Series Centramate cassettes engineered specifically for RNA and Lipid nanoparticle (LNP) applications. The addition of Delta regenerated cellulose membrane, 100 kDa MWCO, offers a solution designed to meet the unique needs - optimizing mass transfer, streamlining of processing times, and maximizing the product yield - of mRNA workflows.
Emmanuel Abate, President Genomic Medicine, Cytiva says: “We created a fit-for-purpose solution accelerating the manufacturing of mRNA therapeutics, which in turn, put those life changing therapies into the hands of patients sooner.”
The new cassette offers a tailored solution for the nuanced steps of Tangential Flow Filtration (TFF) in the production of mRNA and LNP. TFF is needed in mRNA applications for desalting, the removal of impurities and enzymes (for example ribonucleases), buffer exchange (prior to enzymatic capping or chromatography) and/or concentration of the purified product. Their low protein binding enhances process efficiencies significantly. The development and manufacture of RNA therapeutics hinge on the ability to perform ultrafiltration/diafiltration (UF/DF) with precision.
The T-Series cassettes are designed to reduce environmental impact particularly concerning electricity usage - the most substantial environmental aspect of bioprocess manufacturing.
Scott Ripley, Business Leader, Nucleic Acid Therapeutics, Cytiva says: “We’re making strides towards more sustainable production methods. As we continue to optimize runs and yields, we're not only speeding up the process but also cutting down on electricity usage. Oligonucleotide and mRNA therapeutics, powered by growing investment, are revolutionizing and setting new standards for the industry.”
T-series Centramate, Delta, Cytiva and the Drop logo are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva.
About Cytiva
At Cytiva, our mission is to advance and accelerate the development of therapeutics. With 15 000 associates in more than 40 countries, we’re driven to use our expertise and talent to achieve better flexibility, capacity, and efficiency for our customers. Our broad and deep portfolio of tools and technologies, global scale, and best-in-class service provides critical support from discovery to delivery, for customers spanning researchers, emerging biotech, large-scale biopharma and contract manufacturers. Learn more at cytiva.com
Media contact:
[email protected]Tania Kimbal
[email protected]